Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
150 Leser
Artikel bewerten:
(0)

Lenstatin' Introduces The World's First Anti-Cataract Nutritional Supplement

WILMINGTON, N.C., Jan. 20, 2014 /PRNewswire/ --Lenstatin' LLC announces worldwide introduction of the very first nutritional supplement containing Unique Proprietary Antioxidant Blend of micronutrients specifically selected and formulated based on anti-cataractogenic properties.

(Photo: http://photos.prnewswire.com/prnh/20140120/CL49322)

Cataract surgery is the most common therapeutic procedure performed on patients over age 65 in the United States, with over 2 million procedures performed annually. Cataracts are also the leading cause of blindness in the world with over 90% of patients over the age of 65 exhibiting initial signs of cataract.

According to Scott W. Tunis MD FACS, a Board Certified Ophthalmologist and Fellow of The American College of Surgeons with over 30 years experience performing more than 25,000 cataract operations,

"An emerging body of laboratory scientific data suggests that specific antioxidants have beneficial effects on human lens metabolism as well as inhibitory effects on cataract formation and progression. Lenstatin contains a Unique Proprietary Antioxidant Blend of anti-cataract ingredients based on the current scientific data, the exact formula of which is not reproduced by any other eye vitamin preparation in existence."

Symptoms of developing cataract include blurred vision, loss of contrast sensitivity, and difficulty driving at night or reading very fine print. Cataracts can occur in patients in their sixties, fifties, and even forties, and there may be significant interval from the time of diagnosis until elective surgery.

Dr. Tunis states, "Lenstatin should not replace ongoing professional examination or treatment, maintaining a healthy lifestyle and diet, and avoiding prolonged UV exposure. However, in the setting of early cataracts patients should also consider initiating targeted anti-cataract nutritional support with Lenstatin."

For more information visit www.Lenstatin.com.

About Lenstatin LLC
Founded by Scott W. Tunis MD FACS in 2013 to develop ocular disease specific nutraceuticals. Dr. Tunis is a Board Certified Fellow of The American Academy of Ophthalmology, a Fellow of The American College of Surgeons, a member of The American Society of Cataract and Refractive Surgery, and holder of two United States Patents on eye surgery technology.

SOURCE Lenstatin LLC

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.